Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis

European Journal of Neurology

Volumn 17, Issue 10, 2010, Pages 1263-1269

  Lindsey, J W ^a   Hatfield, L M ^a   Vu, T ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

early antigen; Epstein Barr virus; multiple sclerosis; neutralizing antibodies

Indexed keywords

EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 77956641922     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03005.x     Document Type: Article

References (27)

1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007 61: 288 299. (Pubitemid 46676728)
2. Lunemann JD, Munz C. EBV in MS: guilty by association? Trends Immunol 2009 30: 243 248.
3. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000 11: 220 224.
4. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006 67: 2063 2065.
5. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007 6: 773 781.
6. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006 59: 499 503. (Pubitemid 43358070)
7. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006 63: 839 844.
8. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005 293: 2496 2500.
9. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004 62: 2277 2282.
10. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe DM, Howley PM, eds. Fields Virology, 4th edn.
11. Henle W, Henle G, Zajac BA, Pearson G, Waubke R, Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 1970 169: 188 190.
12. Buisson M, Fleurent B, Mak M, et al. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J Clin Microbiol 1999 37: 2709 2714.
13. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985 17: 371 377.
14. Myhr KM, Riise T, Barrett-Connor E, et al. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J Neurol Neurosurg Psychiatry 1998 64: 539 542.
15. Buljevac D, Van Doornum GJ, Flach HZ, et al. Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2005 76: 1377 1381.
16. Riverol M, Sepulcre J, Fernandez-Alonso M, et al. Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. J Neuroimmunol 2007 192: 184 185.
17. Wagner HJ, Hennig H, Jabs WJ, Siekhaus A, Wessel K, Wandinger KP. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol 2000 13: 497 502.
18. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000 55: 178 184.
19. Munch M, Riisom K, Christensen T, Moller-Larsen A, Haahr S. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 1998 97: 171 174. (Pubitemid 28254913)
20. Torkildsen O, Nyland H, Myrmel H, Myhr KM. Epstein-Barr virus reactivation and multiple sclerosis. Eur J Neurol 2008 15: 106 108.
21. Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 1982 43: 730 736.
22. Wilson AD, Morgan AJ. Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. J Virol Methods 1998 73: 11 19.
23. Qualtiere LF, Decoteau JF, Hassan Nasr-el-Din M. Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350220. J Gen Virol 1987 68 (Pt 2 535 543.
24. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 1980 77: 2979 2983.
25. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985 35: 435 438.
26. Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006 129: 1493 1506.
27. Lunemann JD, Huppke P, Roberts S, Bruck W, Gartner J, Munz C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008 71: 1033 1035.